OraQuick Hepatitis C Antibody Test
Cross-source consensus on OraQuick Hepatitis C Antibody Test from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Benefits
Risks & contraindications
Evidence quality
Highlighted claims
- OraQuick is designed for a 20-minute read time under standard use. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- A 5-minute positive antibody result does not prove current viraemia in every person. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- Accuracy is lower among recently cured people because hepatitis C antibodies can persist after sustained virological response. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- Prior research found that a positive OraQuick result at 5 minutes identified all participants with viraemia in pooled cohorts from Canada and Spain. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
- The 5-minute OraQuick approach may reduce unnecessary RNA testing among people non-reactive at 5 minutes. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol